By Spondylitis Association of America
Thursday, March 31, 2016
The following is an announcement from SAA about a third party clinical research study. SAA is not affiliated with this study, the researchers, or the drug manufacturer.
A clinical research study is now recruiting ankylosing spondylitis and axial spondyloarthritis patients between the ages of 18 – 45 who have been experiencing symptoms for less than 5 years.
The purpose of this clinical research study, which is entitled: “Study to Evaluate Maintenance of Sustained Remission of axSpA [Axial Spondyloarthritis] With CZP [Certolizumab Pegol] Compared to Placebo” is to see if the investigational study medication, Certolizumab Pegol (Cimzia) can improve axial spondyloarthritis or ankylosing spondylitis symptoms. It will also test whether that improvement can be maintained after the study drug is reduced or stopped. Participation could last up to 109 weeks.
To learn more and to find out if you pre-qualify, click here
This clinical research study is listed on ClinicalTrials.gov
Learn more about participating in clinical research studies
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.